(Q85018447)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

title

Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

11

U Platzbecker

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

author name string

A A N Giagounidis

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

A Kulasekararaj

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

U Germing

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

R Radkowski

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

S Haase

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

P Petersen

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

G Göhring

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

G Büsche

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

C Aul

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

G J Mufti

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

publication date

30 September 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

13 February 2020

page(s)

855-858

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/leu.2011.268

13 February 2020

exact match

0 references

cites work

Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Treatment of myelodysplastic syndrome with isolated del(5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Persistent malignant stem cells in del(5q) myelodysplasia in remission

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

The response to lenalidomide of myelodysplastic syndrome patients with deletion del(5q) can be sequentially monitored in CD34+ progenitor cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Complex karyotype newly defined: the strongest prognostic factor in advanced childhood myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Secondary myelodysplastic syndrome after fludarabine therapy of a low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.268

7 January 2021

Identifiers

DOI

10.1038/LEU.2011.268

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21960245%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

13 February 2020

0 references

1 reference